These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38332941)

  • 1. Opioid use disorder: current trends and potential treatments.
    Lee YK; Gold MS; Blum K; Thanos PK; Hanna C; Fuehrlein BS
    Front Public Health; 2023; 11():1274719. PubMed ID: 38332941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Treatments for Opioid Use Disorder.
    Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
    JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
    Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 11. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
    Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
    J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
    Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
    Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research.
    Frankeberger J; Jarlenski M; Krans EE; Coulter RWS; Mair C
    Matern Child Health J; 2023 Jul; 27(7):1140-1155. PubMed ID: 36840785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior.
    Mitchell P; Samsel S; Curtin KM; Price A; Turner D; Tramp R; Hudnall M; Parton J; Lewis D
    Soc Sci Med; 2022 Jun; 302():114992. PubMed ID: 35512612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the stigma surrounding opioid use disorder: evaluating an opioid overdose prevention training program applied to a diverse population.
    Bascou NA; Haslund-Gourley B; Amber-Monta K; Samson K; Goss N; Meredith D; Friedman A; Needleman A; Kumar VK; Fischer BD
    Harm Reduct J; 2022 Jan; 19(1):5. PubMed ID: 35034649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
    Muzyk A; Smothers ZPW; Collins K; MacEachern M; Wu LT
    Subst Abus; 2019; 40(4):476-483. PubMed ID: 31418645
    [No Abstract]   [Full Text] [Related]  

  • 20. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.